Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 4

Results For "ICAR"

136 News Found

Rainbow Children's Medicare to set up  around 400 beds in Gurugram
Healthcare | May 15, 2023

Rainbow Children's Medicare to set up around 400 beds in Gurugram

The addition of these two hospitals will provide increased access to specialized pediatric and perinatal care services in the geography


Shilpa Medicare receives USFDA approval for Psoriatic Arthritis Drug
Drug Approval | April 11, 2023

Shilpa Medicare receives USFDA approval for Psoriatic Arthritis Drug

Apremilast Tablets, 10 mg, 20 mg, and 30 mg is a generic equivalent of reference listed drug (RLD) OTEZLA of Celgene.


Shilpa Medicare gets 2 minor observations from USFDA for Unit VII, Analytical Services Division
Drug Approval | March 13, 2023

Shilpa Medicare gets 2 minor observations from USFDA for Unit VII, Analytical Services Division

The company will be submitting the responses to US FDA observations within stipulated timeline


Shilpa Medicare Unit VI Bengaluru facility registered with Ministry of Health, UAE
News | February 17, 2023

Shilpa Medicare Unit VI Bengaluru facility registered with Ministry of Health, UAE

This registration enables companies to register the products (Orodispersible films and Transdermal systems) in UAE for commercialization


Themis Medicare launches Lenzetto for treatment of menopausal symptoms
News | January 04, 2023

Themis Medicare launches Lenzetto for treatment of menopausal symptoms

It ensures sufficient serum estradiol levels to alleviate menopausal symptoms


Glenmark Pharmaceuticals receives ANDA approval for Nicardipine Hydrochloride Capsules
Drug Approval | December 20, 2022

Glenmark Pharmaceuticals receives ANDA approval for Nicardipine Hydrochloride Capsules

According to IQVIA sales data for the 12-month period ending October 2022, the Cardene Capsules, 20 mg and 30 mg market achieved annual sales of approximately US $10.9 million


Shilpa Medicare introduces cancer drug Capecitabine 1000 MG dispersible tablet
News | December 19, 2022

Shilpa Medicare introduces cancer drug Capecitabine 1000 MG dispersible tablet

The product is backed by required scientific proof and comparative bioequivalence studies


Briefs: Piramal Enterprises and Shilpa Medicare
News | December 02, 2022

Briefs: Piramal Enterprises and Shilpa Medicare

Shilpa Medicare Ltd's finished dosage form manufacturing facility, Unit IV, situated at Pharma SEZ, Jadcherla, Telangana has received Health Canada GMP approval


Themis Medicare revenue down 15.26%; Profit down 7.76%
News | November 09, 2022

Themis Medicare revenue down 15.26%; Profit down 7.76%

For the half year ended September 30th, 2022 revenue from operations stood at Rs. 185.44 crore in H1 FY23, as against Rs. 219.89 crore in H1 FY22, a decrease of 15.67%


Shilpa Medicare Hyderabad facility receives US FDA clearance
News | September 23, 2022

Shilpa Medicare Hyderabad facility receives US FDA clearance

The facility is identified as a testing laboratory in numerous ANDAs filed by Shilpa Medicare Limited and its agreed parties